ClinChoice Expands 13-Year Medidata Partnership to Enhance Data Management

Medidata, a Dassault Systèmes brand and a leader in clinical trial solutions for the life sciences industry, has renewed its long-term partnership with ClinChoice, a contract research organization (CRO). Through this new agreement, ClinChoice will utilize the Medidata Platform to optimize study data management and procurement, enhance trial efficiency, and support its growth as a full-service CRO across Asia, Europe, and North America. Additionally, ClinChoice plans to prioritize obtaining Clinical Data Studio accreditation, further advancing its capabilities with an AI-driven data quality management solution.

ClinChoice has been committed to Medidata’s solutions for over a decade, enabling secure connections between patients, sites, and sponsors within a unified cloud environment. As an early adopter, ClinChoice played a vital role during the pandemic by deploying Medidata’s Rave RTSM Direct-to-Patient model. This solution ensured patient access while optimizing inventory management across multiple geographies and adhering to varying regulatory requirements. By continuing to integrate Medidata’s solutions, ClinChoice is enhancing its operational efficiency and positioning itself for growth within the increasingly complex clinical trial ecosystem.

“Since our first deployment of Medidata Rave EDC in 2011, our partnership has supported our growth, beginning in the United States, expanding to China, and ultimately reaching a global scale,” said Ling Zhen, Chairman and CEO of ClinChoice. “We’re excited to broaden our collaboration to include Medidata’s Clinical Data Studio and other advanced technologies to further drive our expansion.”

Medidata’s advanced solutions have empowered ClinChoice to streamline trial operations, enhance efficiency, and expand its global reach. By leveraging Medidata’s tools, ClinChoice aims to accelerate access to life-changing therapies and support global patient care initiatives.

“ClinChoice’s commitment to innovation and their patient-centric approach makes them an invaluable partner,” said Edwin Ng, Senior Vice President and General Manager for APAC at Medidata. “Through this renewed partnership, we look forward to helping ClinChoice utilize Medidata’s solutions to streamline their trial operations, expand their global reach, and accelerate access to critical therapies for patients worldwide.”

About Medidata

Medidata is a leader in digital solutions that support clinical trials, celebrating 25 years of breakthrough technology innovation across more than 35,000 trials and 10 million patients. Offering industry-leading expertise, analytics-driven insights, and the world’s largest patient-level clinical trial data set, Medidata supports over one million users and approximately 2,300 customers. Medidata’s seamless, comprehensive platform improves the patient experience, accelerates clinical breakthroughs, and speeds the path to market for new treatments. Medidata is part of Dassault Systèmes, a global technology company listed on Euronext Paris.

About Dassault Systèmes

Founded in 1981, Dassault Systèmes is a leader in virtual worlds that improve real-life experiences for consumers, patients, and citizens. Its 3DEXPERIENCE platform supports 350,000 customers globally in various industries, helping them collaborate, innovate, and create sustainable solutions.

About ClinChoice

Founded in 1995, ClinChoice is a global contract research organization (CRO) providing comprehensive solutions across the entire development lifecycle for pharmaceutical, biotechnology, medical device, and consumer product companies. With a workforce of 4,000 employees across Asia, Europe, and North America, ClinChoice is dedicated to delivering high-quality clinical trial data, reducing complexity, and accelerating time to market. The company continues to build a global clinical ecosystem, offering deep expertise in clinical development science and regulatory innovation.

Source link

Newsletter Updates

Enter your email address below and subscribe to our newsletter